Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMRNNASDAQ:CCXINASDAQ:INCYNASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRNBioMarin Pharmaceutical$63.69+0.6%$66.15$52.93▼$94.85$12.15B0.31.86 million shs1.30 million shsCCXIChemoCentryx$51.99$51.95$14.95▼$52.00$3.71B1.221.68 million shs113 shsINCYIncyte$62.66+3.7%$63.01$51.75▼$83.95$12.13B0.892.36 million shs2.82 million shsUTHRUnited Therapeutics$303.09+0.8%$304.50$236.65▼$417.82$13.61B0.63448,872 shs784,302 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRNBioMarin Pharmaceutical+0.65%+2.82%-9.90%-0.30%-21.14%CCXIChemoCentryx0.00%0.00%0.00%0.00%0.00%INCYIncyte+3.69%+8.03%+3.48%-15.06%+20.38%UTHRUnited Therapeutics+0.77%+3.28%-1.68%-13.97%+29.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMRNBioMarin Pharmaceutical4.9208 of 5 stars4.33.00.03.33.52.53.1CCXIChemoCentryxN/AN/AN/AN/AN/AN/AN/AN/AINCYIncyte4.7148 of 5 stars3.13.00.03.13.23.33.1UTHRUnited Therapeutics4.9052 of 5 stars3.34.00.04.63.03.33.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMRNBioMarin Pharmaceutical 2.70Moderate Buy$93.1446.24% UpsideCCXIChemoCentryx 0.00N/AN/AN/AINCYIncyte 2.17Hold$73.5317.35% UpsideUTHRUnited Therapeutics 2.67Moderate Buy$390.1728.73% UpsideCurrent Analyst Ratings BreakdownLatest CCXI, UTHR, INCY, and BMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025INCYIncyteWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$58.00 ➝ $59.004/30/2025INCYIncyteRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$64.00 ➝ $67.004/25/2025UTHRUnited TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$395.00 ➝ $314.004/21/2025INCYIncyteJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$70.00 ➝ $68.004/21/2025UTHRUnited TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$357.00 ➝ $355.004/21/2025UTHRUnited TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderperform ➝ Neutral$314.00 ➝ $314.003/24/2025INCYIncyteMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$69.00 ➝ $65.003/18/2025INCYIncyteTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$74.00 ➝ $72.003/18/2025INCYIncyteGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$92.00 ➝ $92.003/18/2025INCYIncyteWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/27/2025UTHRUnited TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$425.00 ➝ $425.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMRNBioMarin Pharmaceutical$2.85B4.26$3.01 per share21.17$29.69 per share2.15CCXIChemoCentryx$32.22M115.14N/AN/A$4.09 per share12.71INCYIncyte$4.24B2.86$0.49 per share128.94$17.82 per share3.52UTHRUnited Therapeutics$2.88B4.73$18.23 per share16.63$127.35 per share2.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMRNBioMarin Pharmaceutical$167.65M$2.2028.9514.610.6114.96%9.91%7.65%5/1/2025 (Estimated)CCXIChemoCentryx-$131.76M-$1.89N/AN/AN/A-357.01%-48.52%-30.59%N/AINCYIncyte$32.62M$0.27232.089.580.410.77%0.05%0.04%N/AUTHRUnited Therapeutics$984.80M$24.6013.3111.030.9740.31%19.22%16.15%N/ALatest CCXI, UTHR, INCY, and BMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025BMRNBioMarin Pharmaceutical$0.95N/AN/AN/A$741.84 millionN/A4/30/2025Q1 2025UTHRUnited Therapeutics$6.29$6.63+$0.34$6.63$726.82 million$794.40 million4/29/2025Q1 2025INCYIncyte$1.01$1.16+$0.15$0.80$996.17 million$1.05 billion2/26/2025Q4 2024UTHRUnited Therapeutics$6.10$6.19+$0.09$6.19$734.74 million$735.90 million2/19/2025Q4 2024BMRNBioMarin Pharmaceutical$0.54$0.72+$0.18$0.64$711.05 million$747.31 million2/10/2025Q4 2024INCYIncyte$1.57$1.09-$0.48$1.02$1.14 billionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMRNBioMarin PharmaceuticalN/AN/AN/AN/AN/ACCXIChemoCentryxN/AN/AN/AN/AN/AINCYIncyteN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMRNBioMarin Pharmaceutical0.115.332.62CCXIChemoCentryx0.024.544.47INCYIncyte0.011.971.94UTHRUnited TherapeuticsN/A4.584.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMRNBioMarin Pharmaceutical98.71%CCXIChemoCentryx81.09%INCYIncyte96.97%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipBMRNBioMarin Pharmaceutical0.85%CCXIChemoCentryx8.30%INCYIncyte17.60%UTHRUnited Therapeutics11.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMRNBioMarin Pharmaceutical3,080190.80 million187.06 millionOptionableCCXIChemoCentryx17871.36 million65.43 millionOptionableINCYIncyte2,320193.52 million159.46 millionOptionableUTHRUnited Therapeutics98044.91 million39.33 millionOptionableCCXI, UTHR, INCY, and BMRN HeadlinesRecent News About These CompaniesUnited Therapeutics (NASDAQ:UTHR) Reports Bullish Q1April 30 at 7:05 PM | msn.comUnited Therapeutics: Strong Financial Performance and Growth Potential Drive Buy RatingApril 30 at 2:34 PM | tipranks.comUnited Therapeutics Corporation (UTHR) Q1 2025 Earnings Call TranscriptApril 30 at 1:20 PM | seekingalpha.comUnited Therapeutics (UTHR) Reports Q1 Earnings: What Key Metrics Have to SayApril 30 at 10:35 AM | zacks.comUnited Therapeutics Corporation Reports First Quarter 2025 Financial Results | UTHR Stock NewsApril 30 at 8:38 AM | gurufocus.comUnited Therapeutics Corp Surpasses Q1 2025 Estimates with $7.18 EPS and $794.4 Million RevenueApril 30 at 8:38 AM | gurufocus.comUnited Therapeutics (UTHR) Surpasses Q1 Earnings ExpectationsApril 30 at 8:38 AM | gurufocus.comUnited Therapeutics Corporation Reports First Quarter 2025 Financial ResultsApril 30 at 8:38 AM | gurufocus.comUnited Therapeutics (UTHR) Q1 Earnings and Revenues Top EstimatesApril 30 at 8:35 AM | zacks.comUnited Therapeutics Corporation Reports First Quarter 2025 Financial ResultsApril 30 at 6:30 AM | businesswire.comVoya Investment Management LLC Grows Holdings in United Therapeutics Co. (NASDAQ:UTHR)April 30 at 5:39 AM | marketbeat.comUnited Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To ExpectApril 29 at 8:28 AM | msn.com2,926 Shares in United Therapeutics Co. (NASDAQ:UTHR) Acquired by Prosperity Consulting Group LLCApril 29 at 6:43 AM | marketbeat.comIntegrated Wealth Concepts LLC Acquires 1,230 Shares of United Therapeutics Co. (NASDAQ:UTHR)April 29 at 5:40 AM | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Stock Position Raised by Price T Rowe Associates Inc. MDApril 29 at 5:15 AM | marketbeat.comLeerink Partnrs Has Bullish Estimate for UTHR Q1 EarningsApril 29 at 1:18 AM | americanbankingnews.comQ1 EPS Forecast for United Therapeutics Lifted by AnalystApril 29 at 1:16 AM | marketbeat.comNitorum Capital L.P. Has $33.67 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)April 28 at 6:46 AM | marketbeat.comSusquehanna Fundamental Investments LLC Takes Position in United Therapeutics Co. (NASDAQ:UTHR)April 28 at 6:45 AM | marketbeat.comNebula Research & Development LLC Invests $1.62 Million in United Therapeutics Co. (NASDAQ:UTHR)April 28 at 6:17 AM | marketbeat.comDark Forest Capital Management LP Makes New $540,000 Investment in United Therapeutics Co. (NASDAQ:UTHR)April 28 at 5:07 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCCXI, UTHR, INCY, and BMRN Company DescriptionsBioMarin Pharmaceutical NASDAQ:BMRN$63.69 +0.41 (+0.65%) As of 04/30/2025 04:00 PM EasternBioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.ChemoCentryx NASDAQ:CCXIChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.Incyte NASDAQ:INCY$62.66 +2.23 (+3.69%) As of 04/30/2025 04:00 PM EasternIncyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.United Therapeutics NASDAQ:UTHR$303.09 +2.33 (+0.77%) As of 04/30/2025 04:00 PM EasternUnited Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
